Construction and characterisation of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits

Vaccine

Volumn 16, Issue 5, 1998, Pages 522-529

  Dalla Pozza, Tania ^a   Yan, Huaru ^a   Meek, Drew ^b   Guzmán, Carlos A ^c   Walker, Mark J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Bordetella pertussis; Oral vaccine; Salmonella typhimurium aroA; Synthetic pertussis toxin operon expression

Indexed keywords

ANTIBODY; LIVE VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; IMMUNIZATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PERTUSSIS; PLASMID; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM;

EID: 0032033284     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)80006-0     Document Type: Article

References (32)

1. 1 Tamura, M., Nagiman, L. and Murau, S. et al. Subunit structure of the islet activating protein in pertussis toxin in the conformity with the A-B model. Biochemistry 1982, 21, 5516-5522.
2. 2 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. A controlled trial of a two-component acellular, a five component acellular and a whole cell pertussis vaccine. N. Engl. J. Med. 1996, 334, 349-355.
3. 3 Greco, D., Salmaso, S. and Mastrantonio, P. et al. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N. Engl. J. Med. 1996, 334, 341-348.
4. 4 Dougan, G. The molecular basis for the virulence of bacterial pathogens: implications for vaccine development. Microbiology 1994, 140, 215-224.
5. 5 Chatfield, S.N., Strugnell, R.A. and Dougan, G. Live salmonellae as vaccines and carriers of foreign antigenic determinants. Vaccine 1989, 7, 495-498.
6. 6 Walker, M.J., Rohde, M., Timmis, K.N. and Guzman, CA Specific lung mucosal and systemic immune responses after oral immunisation of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21 a, and invasive Escherichia coli expressing recombinant pertussis toxin 31 subunit. Infect. Immun. 1992, 60, 4260-4268.
7. 7 Barry, E.M., Gomez-Duarte, O. and Chatfield, S. et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 1996, 64, 4172-4181.
8. 8 Nencioni, L., Pizza, M., Volpini, G., De Magistris, M.T., Giovannoni, F. and Rappuoli, R. Properties of the B oligomer of pertussis toxin. Infect. Immun. 1991, 59, 4732-4734.
9. 9 Guzmán, C.A., Brownlie, R.M., Kadurugamuwa, J., Walker, MJ. and Timmis, K.N. Antibody responses in the lungs of mice following oral immunisation with Salmonella typhimurium aroA and invasive Escherichia coll strains expressing the filamentous hemagglutinin of Bordetella pertussis. Infect. fmmun. 1991, 59, 4391-4397.
10. 10 Strugnell, R., Dougan, G. and Chatfield, S. et al. Characterisation of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis. Infect. Immun. 1992, 60, 3994-4002.
11. 11 Sanderson, K.E. and Stocker, BAD. Salmonella typhimurium strains used in genetic analysis. In: Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, Vol. 2 (Eds Neidhardt, F.C. et al.). American Society for Microbiology, Washington, D.C., 1987, pp. 1220-1224.
12. 12 Hoiseth, S.K. and Stocker, B.A.D. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (London) 1981, 291, 238-239.
13. 13 Kasuga, T., Nakase, Y., Ukishima, K. and Takasu, K. Studies on Haemophilus pertussis. Kitasato Arch. Exp. Med. 1954, 27, 57-62.
14. 14 Guzmán, C.A., Piatti, G., Walker, M.J., Guardati, M.C. and Pruzzo, C. A novel Escherichia coli expression-export vector containing alkaline phosphatase as an insertional inactivation screening system Gene 1994, 148, 171-172.
15. 15 Dalla Pozza, T., Van, H., and Walker, M.J. Expression of a synthetic pertussis toxin operon in Escherichia coli. Vaccine 1997, 15, 968-975.
16. 16 Sambrook, J., Fritsch, E.F. and Maniatis, T. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
17. 17 Munoz, J.J., Arai, H. and Cole, R.L. Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Infect. Immun. 1981, 32, 243-250.
18. 18 Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970, 227, 680-685.
19. 19 Burnette, W.N, 'Western Blotting': Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 1981, 112, 195-203.
20. 20 Walker, M.J., Wehland, J., Timmis, K.N., Raupach, B. and Schmidt, M.A. Characterisation of murine monoclonal antibodies that recognise defined epitopes of pertussis toxin and neutralize its toxic effect on Chinese hamster ovary cells. Infect Immun. 1991, 59, 4249-4251.
21. 21 Witviet, M., Burns, D.L., Brennan, M.J., Poolman, J.T. and Manclark, C.R. Binding of pertussis toxin to eucaryotic cells and glycoproteins. Infect. Immun. 1989, 57, 3330-3342.
22. 22 Kendrick, P.L., Eldering, G., Dixon, M.K. and Lawson, G.M. Mouse protection tests in the study of pertussis vaccine. A comparative series using the intracerebral route for challenge. Am. J. Publ. Hlth 1947, 37, 803-810.
23. 23 Zar, J. H. Biostatistical Analysis, 2nd edn. Prentice Hall, New Jersey, 1984
24. 24 Wall, J.G. and Plückthun, A. Effects of overexpressing folding modulators on the in vivo folding of heterologous proteins in Escherichia coli. Curr. Opin. Biotech. 1995, 6, 507-516.
25. 25 Bergès, H., Joseph-Liauzun, E. and Fayet, O. Combined effects of the signal sequence and the major chaperone proteins on the export of human cytokines in Escherichia coli. Appl. Env. Microbiol. 1996, 62, 55-60.
26. 26 Perez-Perez, J. and Gutierrez, J. An arabinose-inducible expression vector, pAR3, compatible with ColE1-derived plasmids. Gene 1995, 158, 141-142.
27. 27 Weiss, A.A., Johnson, F.D. and Burns, D.L. Molecular characterization of an operon required for pertussis toxin secretion. Proc. Natl Acad. Sci. USA 1993, 90, 2970-2974.
28. 28 Burnette, W.N., Arciniega, J.L. Marr, V.L. and Burns, D.L. Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli. Infect. Immun. 1992, 60, 2252-2256.
29. 29 Walker, M.J., Rohde, M., Wehland, J. and Timmis, K.N. Construction of minitransposons for constitutive and inducible expression of pertussis toxin in favg-negative Bordetella pertussis. Infect. Immun. 1991, 59, 4238-4248.
30. 30 Nencioni, L., Pizza, M. and Bugnoli, M. et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect. Immun. 1990, 58, 1308-1315.
31. 31 Staendner, L.H., Rohde, M., Timmis, K.N. and Guzmán, C.A. Identification of Salmonella typhi promoters activated by invasion of eukaryotic cells. Mol. Microbiol. 1995, 18, 891-902.
32. 32 Dunstan, S.J., Ramsay, A.J. and Strugnell, R.A. Studies of immunity and bacterial invasiveness in mice given a recombinant Salmonella vector encoding murine Interleukin-6. Infect. Immun. 1996, 64, 2730-2736.